Natural History of Spinal Muscular Atrophy Type 1 in Taiwan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

111 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations of the survival motor neuron 1 (SMN1) gene.

The investigators will conduct a systematic review of the contents and activities collected via a comprehensive case report form. Patients who fulfilled diagnostic criteria for SMA type 1 will be reviewed retrospectively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Natural History of Types 2 and 3 SMA in Taiwan

NCT03300869

Spinal Muscular Atrophy

UNKNOWN

Mechanisms of Cell Death in Spinal Muscular Atrophy

NCT01754441

Spinal Muscular Atrophy

COMPLETED

Measuring Levels of SMN in Blood Samples of SMA Patients

NCT00061607

Spinal Muscular Atrophy

COMPLETED

A Registered Cohort Study on SMA

NCT04010604

Spinal Muscular Atrophy

RECRUITING

A Trial of Hydroxyurea in Spinal Muscular Atrophy

NCT00485511

Spinal Muscular Atrophy

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to investigate the natural history of patients with spinal muscular atrophy (SMA) type 1 in Taiwan. This study will provide further insights into the clinical course and pathogenesis of SMA. Several analyses will be conducted regarding overall survival, respiratory support, feeding and nutritional support. The following outcome variables will be examined: correlation between SMA genotype and phenotype, survival, age of onset, and age of confirmed diagnosis, proportion of patients using non-invasive and invasive respiratory support, time to first use of respiratory support, proportion of patients on permanent ventilation, and time to permanent ventilation, number and average duration of hospitalizations, proportion of patients with gastrostomy, number of non-serious and serious respiratory infections, trend of growth parameter (e.g., body weight).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Natural History of Type 1 Spinal Muscular Atrophy (SMA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

type 1 spinal muscular atrophy

The age of onset of patients with type 1 SMA is below 6 months of age.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Jan. 1979\~ 30 Jun. 2014 diagnosed with Spinal Muscular Atrophy (SMA)Type 1
* Onset of paralytic floppy infant less than 6 months of age
* Generalized hypotonia and symmetric weakness, which weakness is more severe in proximal than distal part of extremities
* Weakness in the legs is greater than in the arms
* Tendon reflexes are absent
* Neurogenic changes in electromyogram and/or muscle pathology
* SMN1 gene deletion or mutation